PDT Partners’s Lexeo Therapeutics LXEO Stock Holding History

PDT Partners’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-26,608	Closed	-$241K	–	776
2024 Q3	$241K	Buy	+26,608	New	+$317K	0.02%	635

Other funds holding LXEO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

PDT Partners's LXEO Position: Q4 2024 in Review

PDT Partners sold out of Lexeo Therapeutics (LXEO) in Q4 2024, closing a stake of 26,608 shares — an estimated $241K sold.

PDT Partners first reported a position in LXEO in Q3 2024 and held it in 1 quarter. The position peaked at $241K in Q3 2024. 90 funds tracked by Wall St. Rank hold LXEO as of Q4 2024.

PDT Partners reported no remaining Lexeo Therapeutics position as of Q4 2024 after selling out during the quarter.
PDT Partners sold 26,608 Lexeo Therapeutics shares in Q4 2024, an estimated $241K.
PDT Partners first reported a position in Lexeo Therapeutics in Q3 2024 and held it in 1 quarter.
PDT Partners's Lexeo Therapeutics position peaked at $241K in Q3 2024.
90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.